



## C4 Therapeutics to Participate in Upcoming March Conferences

February 23, 2026 12:10 PM EST

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences.

- **TD Cowen 46<sup>th</sup> Annual Healthcare Conference:**
  - Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts.
- **Barclays 28<sup>th</sup> Annual Global Healthcare Conference:**
  - Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami, Florida.

The live webcasts will be available on the Investors section of the company's website at [www.c4therapeutics.com](http://www.c4therapeutics.com). The archived replays of the webcasts will be available for approximately 90 days following the events.

### About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO<sup>®</sup> platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit [www.c4therapeutics.com](http://www.c4therapeutics.com).

### Contacts:

Investors:

Courtney Solberg

Associate Director, Investor Relations

[CSolberg@c4therapeutics.com](mailto:CSolberg@c4therapeutics.com)

Media:

Loraine Spreen

Senior Director, Corporate Communications & Patient Advocacy

[LSpreen@c4therapeutics.com](mailto:LSpreen@c4therapeutics.com)